QLIDA develops next-generation biomarker diagnostic tests.
Business Model:
Revenue: $0
Employees: 1-10
Address:
City: Philadelphia
State: Pennsylvania
Zip:
Country: United States
QLIDA develops next-generation biomarker diagnostic tests. The company’s proprietary portable, hand-held platform can be used for diagnosis of life-threatening diseases such as cancer and cardiovascular disease, through the use of a nanotechnology-based protein detection. QLIDA has been collaborating with Drexel University to develop its proprietary test, Quantum-dot Linked Immuno-Detection Assay (QLIDA), to create a quantitative biomarker detection platform, enabling early detection of proteins associated with disease. The company is currently developing an ultrasensitive test for cardiovascular disease to be used in point of care testing.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|